Enhanced solute removal with intermittent, in-center, 8-hour nocturnal hemodialysis

Hemodialysis International

Volumn 13, Issue 4, 2009, Pages 487-491

  Troidle, Laura ^a,b   Finkelstein, Fredric ^a,b,c   Hotchkiss, Mark ^a,b   Leypoldt, John Ken ^d  

^a Milford Hemodialysis Center   (United States)

^b Hospital of ST Rapheal   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

2 microglobulin; In center; Kinetics; Nocturnal hemodialysis; Phosphorus

Indexed keywords

BETA 2 MICROGLOBULIN; BICARBONATE; CREATININE; PHOSPHORUS; UREA; WATER;

ADULT; ARTICLE; ARTIFICIAL KIDNEY; BLOOD FLOW VELOCITY; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIALYSATE; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MALE; MEDICAL RESEARCH; PHOSPHATE METABOLISM; SOLUTE; TOTAL BODY WATER; TREATMENT DURATION; TREATMENT OUTCOME;

BETA 2-MICROGLOBULIN; CREATININE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PHOSPHORUS; RENAL DIALYSIS; TIME FACTORS;

EID: 70350539631     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2009.00383.x     Document Type: Article

References (17)

1. Eknoyan G, Beck GJ, Cheung AK. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002, 347:2010-2019.
2. Laurent G, Charra B. The results of an 8 hr thrice weekly haemodialysis schedule. Nephrol Dial Transplant 1998, 13((Suppl 6)):125-131.
3. Charra B, Chazot Jean G, Hurot JM, Vanel T, Terrat JC, VoVan C. Long 3 × 8 hr dialysis. J Nephrol 2003, 16((Suppl 7)):S64-S69.
4. Mucsi I, Hercz G, Uldall R. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 1998, 53:1399-1404.
5. Raj DS, Ouwendyk M, Francoeur K. Beta(2)-microglobulin kinetics in nocturnal hemodialysis. Nephrol Dial Transplant 2000, 15:58-64.
6. Block GA, Hulbert-Shearon TE, Levin NW. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients. Am J Kidney Dis 1998, 31:607-617.
7. Block GA, Klassen PS, Lazarus JM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004, 15:2208-2218.
8. Cheung AK, Levin NW, Greene T. Effects of high-flux hemodialysis on clinical outcomes. J Am Soc Nephrol 2003, 14:3251-3263.
9. Cheung AK, Rocco MV, Yan G. Serum beta-2 microglobulin levels predict mortality in dialysis patients. J Am Soc Nephrol 2006, 17:546-555.
10. Cheung AK, Greene T, Leypoldt JK. Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients. Clin J Am Soc Nephrol 2008, 3:69-77.
11. Leypoldt JK. Kinetics of B2-microglobulin and phosphate during hemodialysis. Semin Dial 2005, 18:410-408.
12. Spalding EM, Chamney PW, Farrington K. Phosphate kinetics during HD. Kidney Int 2002, 61:655-657.
13. Cheung AK, Agodoa LY, Daugirdas JT. Effects of hemodialyzer reuse on clearances of urea and beta-2-microglobulin. The hemodialysis (HEMO) study group. J Am Soc Nephrol 1999, 10:117-127.
14. Ward RA, Greene T, Hartmann B. Resistance to intercompartmental mass transfer limits beta-2-microglobulin removal by post-dilutional hemofiltration. Kidney Int 2006, 69:1431-1437.
15. Troidle L, Hotchkiss M, Finkelstein F. A thrice weekly in-center nocturnal hemodialysis program. Adv Chronic Kidney Dis 2007, 14:244-248.
16. Chen PS, Toribara TY, Warner H. Microdetermination of phosphorus. Anal Chem 1956, 28:1756-1758.
17. Leypoldt JK, Cheung AK, Deeter RB. Single compartment models for evaluating beta 2-microglobulin clearance during hemodialysis. ASAIO J 1997, 43:904-909.